Every Form 4 that Akari Therapeutics Plc (AKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTX filings page.
Akari Therapeutics Plc (symbol: AKTX) is the issuer of record for a Form 4 filing submitted to the SEC.
Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.
Akari Therapeutics Plc reported that interim CFO Farag Kameel D. received a grant of 1,130 American Depositary Shares representing restricted stock units on July 16, 2026, at a reported price of $11.50 per share. According to the footnote, these ADSs represent RSUs, with each RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share, and the RSUs will vest in full on August 16, 2026. Following this award, the interim CFO directly owns 21,581 ADSs.
Akari Therapeutics Plc director and 10% owner Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026 to acquire 22,474 American Depositary Shares (ADSs). These exercises delivered 5,799 and 15,466 ADSs at $0.0004 per ADS and 1,209 ADSs at $8.00 per ADS. The related pre-funded warrant positions reported were reduced to zero, and the transactions are not designated as occurring under a Rule 10b5-1 trading plan. Each ADS represents 80,000 ordinary shares.
Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.
Akari Therapeutics Plc interim CFO Farag Kameel D. received share awards in the form of American Depositary Shares (ADSs) representing ordinary shares. On June 24, 2026, multiple grant/award transactions (code A) increased his direct ADS holdings to 20,452 shares.
A footnote explains these ADS-related awards represent restricted stock units (RSUs), with each RSU giving the right to receive 80,000 ordinary shares. The RSUs vested in full on June 24, 2026, indicating these grants are compensation-related rather than open‑market purchases.
Akari Therapeutics CEO Abizer Gaslightwala reported new stock option awards. On April 1, 2026 he was granted options over 15,563 American Depositary Shares at an exercise price of $14.63 per ADS and options over 5,500 ADS at $4.64 per ADS. Each ADS represents 80,000 ordinary shares. These awards were compensation-related grants rather than open-market share purchases or sales.
Akari Therapeutics director Neal James increased his economic exposure to the company on December 16, 2025 by acquiring derivative securities tied to its American Depositary Shares (ADSs).
He obtained a total of 11,132 warrants and pre-funded warrants to purchase ADSs through a private placement and a note cancellation and exchange agreement. The PIPE pre-funded warrants and accompanying Series G Warrants, as well as additional note-exchange warrants, are exercisable only upon shareholder approval. The pre-funded warrants carry a stated conversion exercise price of $0.00001 per ADS.
Akari Therapeutics (AKTX) reported an insider equity grant by its Interim CFO. On 11/01/2025, the officer acquired 32,000 and 26,619 American Depositary Shares (ADS) at $0.75 per ADS. The filing lists post‑transaction beneficial ownership of 32,000 and 26,619 ADS, held directly.
These ADSs represent restricted stock units (RSUs) that vest on January 1, 2026 and February 15, 2026. Each ADS represents 2,000 ordinary shares.
Akari Therapeutics (AKTX) disclosed a Form 4 showing its Interim CFO acquired 6,277 American Depositary Shares on October 22, 2025, reported as code A at $0.74 per ADS. Following the transaction, 6,277 ADS are beneficially owned with direct ownership.
The filing notes these ADSs represent restricted stock units (RSUs) that vest on October 31, 2025. Each ADS represents 2,000 Ordinary Shares of the company.